跳轉至內容
Merck
全部照片(1)

重要文件

SML3020

Sigma-Aldrich

Taltirelin acetate

≥98% (HPLC)

同義詞:

(4S)-Hexahydro-1-methyl-2,6-dioxo-4-pyrimidinecarbonyl-L-histidyl-L-prolinamide, (S)-N-((S)-1-((S)-2-Carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide, (S)-N-[(Hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide, TA 0910, TA-0910, TA0910

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H23N7O5 · xC2H4O2
分子量::
405.41 (free base basis)
分類程式碼代碼:
12352107
NACRES:
NA.77
暫時無法取得訂價和供貨情況

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to off-white

儲存溫度

−20°C

生化/生理作用

Taltirelin (TA-0910) is a thyrotropin-releasing hormone (TRH) mimetic with greatly enhanced brain-penetration, oral activity and stability. Taltirelin shortens the duration of pentobarbital-induced sleep (0.3-3 mg/kg po. or 0.03-0.3 mg/kg iv.), antagonizes reserpine-induced hypothermia (1 or 3 mg/kg po. or 0.1-0.3 mg/kg ip.), and enhances the spontaneous motor activity (30 mg/kg po.) in mice in vivo, while TRH produces these effects at about 100 times higher doses.
Thyrotropin-releasing hormone (TRH) mimetic with greatly enhanced brain-penetration, oral activity, stability and in vivo efficacy than TRH.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

M Yamamura et al.
Japanese journal of pharmacology, 53(4), 451-461 (1990-08-01)
Effects of orally administered TA-0910, a new thyrotropin-releasing hormone (TRH) analog, on the central nervous system (CNS) were investigated and compared with those of TRH. TA-0910 shortened the duration of pentobarbital-induced sleep and antagonized reserpine-induced hypothermia at 0.3 mg/kg or
John P Dougherty et al.
Behavioural brain research, 360, 255-261 (2018-12-12)
Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention. To identify and develop such interventions, and to better understand fatigue, additional preclinical research is necessary. However, despite
Cong Zheng et al.
Frontiers in cellular neuroscience, 12, 485-485 (2019-01-09)
Dopaminergic neurons loss is one of the main pathological characters of Parkinson's disease (PD), while no suitable neuroprotective agents have been in clinical use. Thyrotropin-releasing hormone (TRH) and its analogs protect neurons from ischemia and various cytotoxins, but whether the

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務